Vaccine makers Pfizer and Moderna may tap €5bn from annual booster shots

Vaccine makers Pfizer, BioNTech, and Moderna are expected to reap billions of euros from Covid-19 booster shots.

Drugmakers Pfizer, BioNTech, and Moderna are expected to reap billions of euros from Covid-19 booster shots in a market that could rival the $6bn (€5bn) in annual sales for flu vaccines for years to come, analysts and healthcare investors say.

For several months, the companies have said they expect that fully inoculated people will need an extra dose of their vaccines to maintain protection over time and to fend off new coronavirus variants.